Financials

	2022	2023
Net sales	54.13M 47.22M 44.44M 40.49M 75.95M 5.19B 76.03M 532M 205M 2.64B 203M 199M 8.52B	80.75M 70.45M 66.29M 60.41M 113M 7.74B 113M 794M 306M 3.94B 303M 297M 12.71B
Net income	-18.11M -15.8M -14.86M -13.55M -25.41M -1.73B -25.43M -178M -68.58M -884M -68.01M -66.5M -2.85B	-20.13M -17.56M -16.53M -15.06M -28.25M -1.93B -28.28M -198M -76.25M -982M -75.62M -73.94M -3.17B
Net Debt	42.09M 36.72M 34.55M 31.49M 59.06M 4.03B 59.12M 414M 159M 2.05B 158M 155M 6.62B	55.34M 48.28M 45.43M 41.4M 77.65M 5.3B 77.73M 544M 210M 2.7B 208M 203M 8.71B

* Estimated data More financial data

Company Profile

Alimera Sciences, Inc. is a global pharmaceutical company. The Company is focused on helping patients, physicians and partners concerned with retinal health and maintaining better vision longer.

Employees

157

Sector

Pharmaceuticals

More about the company

Market Closed - Nasdaq 16:00:00 2024-09-13 EDT			5-day change	1st Jan Change
5.540 ^USD	-0.18%		-.--%	-

24-09-16	ANI Pharmaceuticals Completes Purchase of Alimera Sciences, Sees 'Substantially Higher' Earnings After Deal	MT
24-09-15	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from NASDAQ Composite Index	CI

Market Cap	301M 263M 247M 225M 423M 28.86B 423M 2.96B 1.14B 14.7B 1.13B 1.11B 47.41B	P/E 2022	-1.05x	P/E 2023	-5.16x
Enterprise Value	357M 311M 293M 267M 500M 34.17B 501M 3.51B 1.35B 17.4B 1.34B 1.31B 56.11B	EV / Sales 2022	1.13x	EV / Sales 2023	3.49x
Free-Float	94.65%	Yield 2022 *	-	Yield 2023	-

24-09-16	ANI Pharmaceuticals Completes Purchase of Alimera Sciences, Sees 'Substantially Higher' Earnings After Deal	MT
24-09-15	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from NASDAQ Composite Index	CI
24-09-15	ANI Pharmaceuticals, Inc. completed the acquisition of Alimera Sciences, Inc. from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.	CI
24-09-11	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Looming CPI Data Likely to Provide Rate-Cut Clues	MT
24-09-11	ANI Pharmaceuticals, Alimera Sciences to Close Merger Next Week	MT
24-09-10	Alimera Sciences Sues ANI Pharmaceuticals for Delays in Merger Close	MT
24-09-09	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from S&P TMI Index	CI
24-08-06	Alimera Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-07-17	Processa Pharmaceuticals Appoints Russell Skibsted as CFO	MT
24-06-30	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell Small Cap Comp Value Index	CI
24-06-30	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell Small Cap Completeness Index	CI
24-06-30	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell 2000 Index	CI
24-06-30	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell 3000E Index	CI

24-06-25	Maxim Downgrades Alimera Sciences to Hold From Buy	MT
24-06-25	Alliance Global Partners Downgrades Alimera Sciences to Neutral From Buy, Adjusts Price Target to $5.50 From $8	MT
24-06-25	Craig-Hallum Downgrades Alimera Sciences to Hold From Buy, Price Target is $5.50	MT
24-06-25	HC Wainwright Downgrades Alimera Sciences to Neutral From Buy, Price Target is $6	MT
24-03-25	Maxim Initiates Alimera Sciences at Buy Rating With $10 Price Target	MT

Alimera Sciences, Inc. Stock

Stocks

ALIM

US0162592028

Pharmaceuticals

Valuation: Alimera Sciences, Inc.

Latest news: Alimera Sciences, Inc.

Analysts' recommendations: Alimera Sciences, Inc.

Press Releases: Alimera Sciences, Inc.

News in other languages: Alimera Sciences, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Alimera Sciences, Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

24-09-16	ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences	AQ
24-09-11	ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger	BU
24-09-11	ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger	AQ
24-09-10	ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences	AQ
24-09-10	Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement	BU

Manager	Title	Age	Since
Elliot Maltz DFI	Director of Finance/CFO	41	2024-01-01
Jason Werner COO	Chief Operating Officer	48	2023-10-01
Laura Cegala HRO	Human Resources Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/16/24	Margaret Pax	Issuer sale	Director	36,713	0.0675%
9/16/24	Velan Capital Investment Management LP	Issuer sale	Company	14,408,533	26.4940%
9/16/24	David Holland	Issuer sale	Chief Marketing Officer & SVP	1,232,852	2.2669%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALIMERA SCIENCES, INC.	-0.18%	-.--%	-.--%	+78.14%	287M
REGENERON PHARMACEUTICALS, INC.	+1.70%	+2.13%	+34.83%	-4.02%	78.37B
MODERNA, INC.	+12.27%	+20.12%	+585.18%	+67.04%	61.5B
CSL LIMITED	+1.54%	+6.70%	-10.12%	-32.11%	59.78B
SAMSUNG BIOLOGICS CO.,LTD.	+0.29%	-0.92%	-10.95%	+26.82%	46.53B
UCB	+1.92%	+3.16%	+4.33%	+150.18%	45.5B
BIOGEN INC.	+1.66%	+0.88%	+53.73%	-15.91%	31.84B
INCYTE CORPORATION	-0.53%	+2.62%	+44.05%	+106.48%	25.4B
INNOVENT BIOLOGICS, INC.	+6.00%	+9.46%	+11.24%	+166.67%	21.43B
SWEDISH ORPHAN BIOVITRUM AB	-0.76%	+1.19%	+57.98%	+102.93%	15.77B
Average	+1.15%	+1.56%	+77.03%	+64.62%	38.64B
Weighted average by Cap.	+1.22%	+1.66%	+108.14%	+44.99%

3 years	2.61	5.65
5 years	1.3	7.92
10 years	0	25.8